Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, and glucagon) currently in clinical trials for obesity and type 2 diabetes
Stability timeframes circulating online including commonly cited figures such as 28 days are unverified and should not be treated as clinical guidance
In contrast, co-treatment of semaglutide with the amylin receptor agonist cagrilintide resulted in 29% of patients with obesity and T2D reporting nausea compared to 13% for cagrilintide alone and 16% for semaglutide alone (68)
Few suppliers currently offer this specific combination, making it a differentiator for Simple Peptide
Average duration of GLP-1 based therapies was 20.5 weeks
Tell your health care provider right away if you get symptoms which may include: pain in your upper stomach (abdomen), fever, yellowing of the skin or eyes (jaundice), or clay-colored stools food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)